Overview

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Manhattan Psychiatric Center
Collaborator:
Nathan Kline Institute for Psychiatric Research
Treatments:
Quetiapine Fumarate